Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
Haploidentical hematopoietic stem cell transplantation irrespective of the conditioning and
graft-versus-host disease prophylaxis is associated with high frequency of primary and
secondary graft failure. Different technologies of with replete or depleted graft are
associated with 10-20% of graft failures. Fludarabine and busulfan conditioning is the most
commonly used approach for a variety of disease. Furthermore combination of fludarabine and
bendamustine was sufficient to facilitate engraftment in patients with chronic lymphocytic
leukemia and lymphomas. The aim of the study is to evaluate whether addition of bendamustine
to fladarabine and busulfan conditioning reduces the risk of primary graft failure after
haploidentical allograft.